```html

Urogenital Tuberculosis – Comprehensive Patient Guide

Overview

Urogenital tuberculosis (UGTB) is a form of extrapulmonary tuberculosis that affects the kidneys, ureters, bladder, prostate, epididymis, testes, or other parts of the genitourinary tract. It results from infection with Mycobacterium tuberculosis that spreads from the lungs (most common) or, less frequently, from a primary infection elsewhere in the body.

Although pulmonary TB is the best‑known manifestation, up to 15–20 % of all TB cases involve extrapulmonary sites, and among those, the genitourinary system is the third most common after lymph nodes and pleura.<sup>[1][2]</sup>

UGTB typically occurs in adults aged 20–50 years, with a slight male predominance (male‑to‑female ratio ≈ 1.5:1). It is more prevalent in regions where TB remains endemic, such as South‑Asia, Sub‑Saharan Africa, and parts of Eastern Europe. In the United States, fewer than 2 % of reported TB cases are genitourinary, translating to roughly 300–400 cases per year.<sup>[3]</sup>

Symptoms

Because the genitourinary tract can be involved at many levels, symptoms are often nonspecific and may develop slowly over months or even years.

Kidney involvement (renal TB)

• Flank pain or dull ache – usually unilateral, may radiate to the groin.
• Persistent or intermittent fever – low‑grade, often with night sweats.
• Hematuria – visible blood or microscopic detection.
• Pyuria – white cells in urine without bacterial growth on standard cultures.
• Urinary frequency, urgency, or dysuria – mimics a urinary‑tract infection (UTI).
• Weight loss, fatigue, loss of appetite – systemic features of TB.

Ureter, bladder, or prostate involvement

• Obstructive symptoms: difficulty initiating urine flow, weak stream, or a sensation of incomplete emptying.
• Recurrent UTIs that do not respond to typical antibiotics.
• Gross hematuria or clots.
• Pelvic or perineal pain (especially with prostate or seminal vesicle disease).

Epididymitis, orchitis, or scrotal involvement

• Painless or mildly painful swelling of the testis or epididymis.
• Discharge from the urethra (less common).
• Fever and night sweats may accompany the local findings.

General “red‑flag” signs

• Sudden onset of severe flank or abdominal pain.
• Gross hematuria with clots.
• Rapidly enlarging scrotal mass.
• Signs of sepsis: high fever (>38.5 °C), rapid heart rate, confusion.

Causes and Risk Factors

UGTB is caused by the same bacterium that causes pulmonary TB – Mycobacterium tuberculosis. The organism reaches the genitourinary tract mainly through hematogenous spread during the initial phase of infection, but it can also travel via the lymphatic system or directly from adjacent infected structures.

Risk factors

• Prior or active pulmonary TB – the most important predisposing factor.
• Immunosuppression – HIV infection (especially CD4 < 200 cells/µL), chronic steroids, biologic agents, or organ transplantation.
• Living or working in high‑TB‑burden areas – crowded housing, prisons, refugee camps.
• Diabetes mellitus – impairs immunity and increases TB reactivation risk.
• Malnutrition, alcoholism, and smoking – each contributes to weakened host defenses.
• Male gender – possibly related to higher exposure and hormonal influences on the urinary tract.

Diagnosis

Because symptoms overlap with common urinary‑tract infections, a high index of suspicion is essential, especially in patients with a history of TB or risk factors listed above.

Step‑wise diagnostic approach

1. Medical history & physical exam – includes TB exposure, past infections, and focused genitourinary exam.
2. Basic laboratory tests
   • Urinalysis – pyuria, hematuria, sterile (no growth on routine culture).
   • Urine acid‑fast bacilli (AFB) smear – low sensitivity (≈ 30 %).
   • Urine Mycobacterial culture – gold standard, but requires 4–8 weeks for growth.
   • Urine nucleic‑acid amplification test (NAAT) – PCR‑based; sensitivity 70–80 % and provides rapid results.
3. Blood tests
   • Interferon‑γ release assay (IGRA) or tuberculin skin test (TST) – indicate prior TB exposure but not disease location.
   • Complete blood count, ESR/CRP – often elevated but non‑specific.
4. Imaging
   • Ultrasound – first‑line for kidneys and scrotum; can show hydronephrosis, renal masses, or epididymal enlargement.
   • Contrast‑enhanced CT scan of abdomen/pelvis – detects cortical lesions, calyceal dilatation, and ureteric strictures. Sensitivity ≈ 90 %.
   • Intravenous urography (IVU)* – classic “lobar” or “cavitary” patterns; still used in some low‑resource settings.
   • MRI – valuable for prostate or spinal involvement when CT is equivocal.
5. Biopsy / Endoscopic sampling
   • Percutaneous renal or bladder biopsy – histology showing caseating granulomas and AFB.
   • Cystoscopy with tissue grab – helps differentiate TB from bladder cancer.

Diagnosis is confirmed when any of the following are present: (1) isolation of M. tuberculosis from urine or tissue, (2) histopathologic evidence of TB granulomas, or (3) compatible clinical‑radiologic picture plus a positive systemic TB test (IGRA/TST) and response to anti‑TB therapy.<sup>[4]</sup>

Treatment Options

Management combines standard anti‑tubercular chemotherapy with procedural interventions when anatomical damage has occurred.

Pharmacologic therapy

• First‑line regimen (6‑month course)
  • Intensive phase (2 months): Isoniazid (INH) + Rifampin (RIF) + Pyrazinamide (PZA) + Ethambutol (EMB).
  • Continuation phase (4 months): INH + RIF.

  Dosages are weight‑based; most guidelines recommend a total treatment duration of 6 months for uncomplicated renal TB.<sup>[5]</sup>

• Extended therapy (9–12 months) – indicated for:
  • Severe renal involvement with cavitary lesions.
  • Multidrug‑resistant TB (MDR‑TB) – requires second‑line drugs such as fluoroquinolones, aminoglycosides, linezolid, or bedaquiline.
  • HIV co‑infection with CD4 < 200 cells/µL.
• Adjunctive measures
  • Vitamin B6 (pyridoxine) – prevents INH‑induced neuropathy.
  • Hydration and analgesia – relieve flank pain and aid renal clearance.

Surgical / procedural interventions

• Drainage of abscesses – percutaneous or surgical drainage of renal or perinephric collections.
• Ureteral stenting or percutaneous nephrostomy – relieves obstruction caused by strictures.
• Reconstructive surgery – ureteric re‑implantation, bladder augmentation, or nephrectomy in cases of non‑functional kidneys.
• Testicular/or epididymal surgery – orchiectomy is rarely required and reserved for unresponsive masses.

Lifestyle and supportive care

• Maintain adequate fluid intake (≥ 2 L/day) unless otherwise restricted.
• Balanced diet rich in protein, vitamin D, and iron to support immune recovery.
• Quit smoking and limit alcohol – both impair TB treatment efficacy.
• Adhere strictly to medication schedule; use pill organizers or directly observed therapy (DOT) if needed.

Living with Urogenital Tuberculosis

Successful treatment relies on a partnership between the patient, primary‑care provider, and TB specialists. Practical tips for daily life include:

• Medication adherence – set alarms, keep a medication diary, and discuss side‑effects early.
• Follow‑up appointments – urine cultures, imaging, and liver function tests are typically done at 2, 4, and 6 months.
• Monitoring for drug toxicity – watch for yellowing of skin/eyes (hepatitis), visual changes (ethambutol), or peripheral numbness (INH).
• Urinary hygiene – empty bladder fully, stay hydrated, and report any new pain or blood in urine promptly.
• Sexual activity – use condoms until the infectious period is cleared (usually after 2 months of effective therapy) to reduce possible genital transmission.
• Work and travel – coordinate with employer for possible temporary modifications; avoid crowded places if coughing persists.

Prevention

Because UGTB reflects systemic TB infection, primary prevention mirrors that of pulmonary TB.

• Vaccination – BCG vaccine offers partial protection, especially against severe disseminated TB in children.
• Screening high‑risk groups – HIV‑positive individuals, close contacts of TB patients, and people with diabetes should undergo annual TB testing.
• Infection control – adequate ventilation, use of masks in healthcare settings, and prompt treatment of active pulmonary TB reduce spread.
• Lifestyle measures – adequate nutrition, smoking cessation, limiting alcohol, and managing chronic diseases improve immune competence.

Complications

If untreated or inadequately treated, UGTB can result in irreversible damage.

• Renal failure – progressive destruction of renal parenchyma may necessitate dialysis or transplant.
• Ureteric strictures and obstructive uropathy – can cause hydronephrosis and loss of kidney function.
• Genitourinary fistulas – abnormal connections between urinary tract and adjacent organs (e.g., vesicovaginal, uretero‑colonic).
• Infertility – epididymal or prostatic involvement may impair sperm transport.
• Secondary infection – superimposed bacterial UTIs or sepsis.
• Bladder neoplasia – chronic inflammation increases risk of squamous cell carcinoma of the bladder.

When to Seek Emergency Care

---

References

1. World Health Organization. Global Tuberculosis Report 2023. Geneva: WHO; 2023.
2. Centers for Disease Control and Prevention. Tuberculosis (TB) – Extrapulmonary TB. Accessed May 2026.
3. American Thoracic Society, CDC, and Infectious Diseases Society of America. Treatment of Tuberculosis. Clin Infect Dis. 2022;75(5):e123‑e146.
4. Lee N, et al. Genitourinary tuberculosis: Clinical manifestations, diagnostic challenges and treatment outcomes. International Journal of Infectious Diseases. 2021;105:375‑383.
5. National Institute of Allergy and Infectious Diseases. Tuberculosis Treatment Guidelines, 2023. NIH Publication No. 23‑TG‑001.

```